IDH1 mutations occur in approximately 60 - 80% of diffusely infiltrating gliomas of the WHO grades II and III and in secondary GBM but only in around 5% of primary GBM [11,18-22]. The gene discussed is IDH1; the disease is central nervous system cancer.